FDA Issues Warning Letters And Test Results for Cannabidiol-Related Products
By
Posted on
FDA has tested the chemical content of cannabinoid compounds in some of the products
Over the past several years, FDA has issued several warning letters to firms that market unapproved new drugs that allegedly contain cannabidiol (CBD). As part of these actions, FDA has tested the chemical content of cannabinoid compounds in some of the products, and many were found to not contain the levels of CBD they claimed to contain. It is important to note that these products are not approved by FDA for the diagnosis, cure, mitigation, treatment, or prevention of any disease. Consumers should beware purchasing and using any such products.
| Firm | State | Purchase Website |
|---|---|---|
| Honest Globe, Inc. | CA | elixicure.com |
| BioLyte Laboratories, LLC | MI | N/A |
| Cannafy | AZ | cannafyl.com |
| Evolved Ayurvedic Discoveries Inc./BioCBDPlus | CA | biocbdplus.com |
Source: FDA
